Digestive System
Conditions
Interventions
Vitamin E group
Roflumilast group
Sponsors
Tanta University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1-Patients with Cytokeratine level >240 IU/L. 2-Adult patient (age > 18 years old). 3-Both sex. 4-Overweight and obese subjects. 5-Patients with evidence of steatosis through imaging. 6-Patient with mild to moderate elevation in aminotransferase activity (>2 ,but 36. 8-Patient with HAIR ( hypertension ,alanine aminotransferase level ,insulin resistance) of 2 or 3 . 9-Patients with fibroscan score >7Kpa and < 12.5 Kpa (F2 – F3).
Exclusion criteria
Exclusion criteria: 1- Alcohol consumers. 2-Smokers. 3-Patients with Wilson`s disease and hemochromatosis. 4-Patients with viral hepatitis. 5-Patients with cirrhosis. 6-Patients with inflammatory diseases. 7-Patients with other comorbid disease that elevate transaminases (congestive heart failure and malignancy). 8-Patients on medications that interfere with lipid and carbohydrate metabolism. 9-Patients on stateogenic medications, pregnant and lactating women and females on oral contraceptive pills.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was the change in liver stiffness measurement (LSM) (fibro scan score). | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome was the change in the biological markers . | — |
Countries
Egypt
Contacts
Public ContactSherif Mohamed Abd elsalam
Professor of tropical medicine and infectious diseaseFaculty of MedicineTanta UniversityTanta Egypt
Outcome results
None listed